Alyeska Investment Group L.P. Has $80.26 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Alyeska Investment Group L.P. boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 0.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,641,392 shares of the company's stock after purchasing an additional 16,392 shares during the period. Alyeska Investment Group L.P. owned 0.32% of Teva Pharmaceutical Industries worth $80,256,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TEVA. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $44,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Teva Pharmaceutical Industries in the third quarter worth $50,000. Ameliora Wealth Management Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $66,000. Finally, IFP Advisors Inc boosted its position in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after purchasing an additional 1,960 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on TEVA shares. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Barclays dropped their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Finally, Bank of America reduced their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $16.22 on Friday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The company's fifty day moving average price is $15.11 and its 200 day moving average price is $17.49. The company has a market capitalization of $18.39 billion, a PE ratio of -11.19, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.